CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 72053-72207 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/2008f024274c53b0de1276f4047a6a641813fd98","sourcedb":"CORD-19","sourceid":"2008f024274c53b0de1276f4047a6a641813fd98","text":"DX-88 met its primary endpoint; 72% of DX-88 patients had a significant improvement within 4 hours, (placebo response rate 25%, difference 47% p= 0.0169).","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"T27482","span":{"begin":0,"end":154},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T27482","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T194","span":{"begin":0,"end":154},"obj":"Sentence"}],"attributes":[{"subj":"T194","pred":"source","obj":"CORD-19_Custom_license_subset"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#eccd93","default":true},{"id":"CORD-19_Custom_license_subset","color":"#b293ec"}]}]}}